BMS-5
BMS-5 性质
| 密度 | 1.54±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | Sealed in dry,Store in freezer, under -20°C |
| 溶解度 | DMSO:PBS (pH 7.2) (1:5):0.2(最大浓度 mg/mL);0.46(最大浓度 mM) 乙醇:3.0(最大浓度 mg/mL);6.96(最大浓度 mM) 。 mM） |
| 酸度系数(pKa) | 9.51±0.50(Predicted) |
| 形态 | 白色粉末 |
| 颜色 | 白色至米白色 |
BMS-5 用途与合成方法
| Target | Value |
|
LIMK1
(Cell-free assay) | 7 nM |
|
LIMK2
(Cell-free assay) | 8 nM |
BMS-5 (LIMKi 3) inhibits cofilin-Ser3 phosphorylation in a dose-dependent manner in Nf2 ΔEx2 mouse Schwann cells (MSCs) with an IC 50 of ~2 µM. BMS-5 (LIMKi 3) reduces Nf2 ΔEx2 MSC viability in a dose-dependent manner with an IC 50 of 3.9 µM, but does not significantly reduce the viability of control Nf2 flox2/flox2 MSCs at equivalent BMS-5 concentrations. At 10 µM BMS-5, Nf2 ΔEx2 MSC viability is 40% compared to 83% for controls.
BMS-5 (LIMKi 3) (20 or 200 μM/side) is bilaterally infused into the hippocampus of rats immediately after contextual fear conditioning training. Rats are tested for memory consolidation 48 h after fear conditioning. Post hoc analysis shows that the group treated with 200 μM BMS-5 express lower freezing levels compared to the 20 μM and vehicle groups (P<0.01).
BMS-5 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | S0185 | BMS-5 | 1338247-35-0 | 5mg | 857.46 |
| 2024-04-30 | S0185 | BMS-5 | 1338247-35-0 | 25mg | 1775.47 |
